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Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a
signiﬁcantlikelihoodoftreatmentfailureandprostatecancer-speciﬁcmortality(PCSM).Theresultsofmultiplelarge,prospective,
randomizedtrialshavedemonstratedthatmenwithhigh-riskfeatureswhoaretreatedinamultimodalfashionatthetimeofinitial
diagnosis have improved overall survival. Advances in local treatments such as dose-escalated radiotherapy in conjunction with
androgen suppression and postprostatectomy adjuvant radiotherapy have also demonstrated beneﬁts to this subset of patients.
However, therapeutic enhancement with the addition of chemotherapy to the primary treatment regimen may help achieve
optimal disease control.
1.Introduction
Prostate cancer is the most common noncutaneous malig-
nancy and is the second leading cause of cancer-related
mortality among men in the USA [1]. In 2010, it is estimated
that217,730menwerenewlydiagnosedand32,050mendied
ofprostatecancer[2].Simplystated,roughly1in6American
men will be confronted with a diagnosis of prostate cancer
during their lifetime. Prostate cancer exhibits a broad spec-
trum of clinical behaviors, ranging from microscopic, well-
diﬀerentiated indolent tumors to aggressive malignancies
withsigniﬁcantpotentialforrecurrenceandmetastasis.Most
prostate cancers are localized at the time of diagnosis which
is likely to continue with increasing emphasis on screening
and improving technology for early detection.
Historically, patients with localized prostate cancer were
categorized primarily based on clinical staging and whether
or not they were considered surgical candidates. Thus,
the term “localized” generally referred to stage T1-T2
disease which was managed with local therapy (surgery,
radiotherapy) or active surveillance. “Locally advanced”
disease referred to stage T3-T4 disease which was considered
inoperable. However, a better understanding of the natural
history of prostate cancer and advances in both the quality
and quantity of available treatment options have allowed
clinicians to develop more sophisticated risk stratiﬁcation
systems (Table 1).
Current risk stratiﬁcation of prostate cancer patients is
based upon the likelihood of recurrence after locoregional
treatment (Table 2). Various pretreatment parameters have
been studied as potential prognostic factors to help identify
subsets of patients, speciﬁcally, among high-risk patients
in whom treatment failure is more likely. Prostate-speciﬁc
antigen (PSA) has been one of the most extensively studied
parameters (PSA velocity, PSA doubling time) but remains
a source of controversy, particularly with regards to its
utility in screening at-risk patients. While PSA can provide
general information about the aggressiveness of the tumor
or treatment response of a patient’s disease, its predictive
value alone remains relatively low. The incorporation of pre-
treatment PSA and the Gleason score in combination with
clinical staging has served to better prognosticate patient
outcomes. In a multi-institutional study of 4133 prostate
cancer patients, combining preoperative serum PSA levels
with the Gleason score and clinical stage was able to more
accurately predict capsular penetration, involvement of sem-
inalvesiclesandpelviclymphnodes[3].Severalpriorstudies
have conﬁrmed that PSA > 10ng/mL and/or Gleason scores
> 7 result in a 5-year recurrence risk of approximately 70%.
Furthermore, men with high-risk features at presentation2 Advances in Urology
Table 1: Anatomic stage/prognostic groups, high-risk localized prostate cancer.
Group T N M PSA Gleason
I T1a–c N0 M0 PSA < 10 Gleason ≤ 6
T2a N0 M0 PSA < 10 Gleason ≤ 6
T1-2a N0 M0 PSA X Gleason X
IIA T1a–c N0 M0 PSA < 20 Gleason 7
T1a–c N0 M0 10 ≤ PSA < 20 Gleason ≤ 6
T2a N0 M0 10 ≤ PSA < 20 Gleason ≤ 6
T2a N0 M0 PSA < 20 Gleason 7
T2b N0 M0 PSA < 20 Gleason ≤ 7
T2b N0 M0 PSA X Gleason X
IIB T2c N0 M0 AnyPSA AnyGleason
T1-2 N0 M0 PSA ≥ 20 AnyGleason
T1-2 N0 M0 AnyPSA Gleason >8
III T3a-b N0 M0 AnyPSA AnyGleason
IV T4 N0 M0 AnyPSA AnyGleason
Any T N1 M0 Any PSA Any Gleason
Any T Any N M1 Any PSA Any Gleason
Adapted from American Joint Committee on Cancer (AJCC Cancer Staging Manual, Seventh Edition, 2010).
Table 2: Prognostic factors for recurrence risk in localized prostate cancer.
Very low Low Intermediate High Very high (locally advanced)
T1c T1-T2a T2b-T2c T3a T3b-T4
Gleason < 6 Gleason 2–6 Gleason = 7 Gleason 8–10
PSA < 10 PSA < 10 PSA 10–20 PSA > 20
<3 (+) biopsy cores w/ ≤ 50% cancer per core
PSA density < 0.15ng/mL/g
Adapted from NCCN Clincal Practice Guidelines in Oncology Prostate Cancer V.1.2011 c  2011 National Comprehensive Cancer Network, Inc.
have a signiﬁcantly higher risk of recurrence, metastatic
disease and prostate-cancer-related mortality [4–10].
A recent European multi-institutional study by Spahn
et al. highlighted the need to further deﬁne the high-risk
population in order to deliver the most appropriate therapy
to each patient. In this study, 712 high-risk patients with
PSA > 20ng/mL underwent radical prostatectomy with
bilateral pelvic lymph node dissection between 1987 and
2005. Patients were stratiﬁed into four subgroups based on
the number of additional risk factors present (none, biopsy
Gleason score ≥ 8, clinical stage 3-4, or both) to assess which
risk factors improved prediction of treatment failure and
PCSM. The biopsy Gleason score was the strongest predictor
of progression and mortality. Among high-risk patients with
PSA > 20ng/mL, those with Gleason scores < 8 had a 10-
year PCSM of 5%, while those with Gleason scores ≥ 8h a da
PCSM of 35%. Importantly, this study reports that men with
PSA > 20ng/mL and a Gleason score < 8 are at minimal risk
forPCSMandmayrepresentaspeciﬁcsubgroupofhigh-risk
patients that should be considered for surgery [11].
Similarly, a retrospective study by Walz et al. reported
that the number of risk factors (T3 disease, Gleason ≥
8, D’Amico high-risk group, PSA ≥ 20ng/mL) present
inﬂuences the 5-year biochemical recurrence risk in the
postradical prostatectomy setting. The rate of favorable
pathology and recurrence after surgical intervention is
dependent upon the criteria used to deﬁne high-risk disease
as well as the conglomeration of risk factors present in each
patient [12]. Taken altogether, this suggests that there is
still much to learn about high-risk disease and that further
characterization of this risk group is necessary in order to
optimize treatment.
The most current guidelines deﬁne high-risk localized
prostate cancer as patients with clinical stage T3 disease, a
Gleason score of 8–10 or a PSA level > 20ng/mL (Table 3).
Additionally, the National Comprehensive Cancer Network
(NCCN) has deﬁned very high-risk (locally advanced)
patients as those with clinical stage T3b and T4 disease
without evidence of nodal or metastatic involvement [13–
17]. For the purposes of this paper and the discussion of
therapeutic management, both high-risk and very high-risk
subgroups will be considered together. While no consensus
exists with regards to optimal treatment for this subset of
patients, it is clear that a multidisciplinary and multimodal
therapeutic approach is crucial for proper management of
high-risk localized prostate cancer. This paper will focus
upon current treatment modalities as well as therapeutic
options on the horizon for high-risk patients.Advances in Urology 3
Table 3: Risk stratiﬁcation for high-risk prostate cancer.
Source High-risk deﬁnition
D’Amico et al. [13] Stage T2c or PSA > 20ng/mL or Gleason > 8
RTOG 9902, 0521 [14, 15] Any T stage, PSA 20–100ng/mL, Gleason > 7o rs t a g e≥ T2, PSA < 100ng/mL,
Gleason 8–10
NCCN (v1.2011) [16] Stage ≥ T3 and/or PSA > 20ng/mL and/or Gleason 8–10∗
Adapted from Nat Rev Urol 2010 Nature Publishing Group [17]. ∗Combines high-risk and very high risk (locally advanced) groups.
2. Rationale for a Multimodal Approach for the
Treatment of High-Risk ProstateCancer
Traditionally, single modality regimens for treating high-
risk patients have resulted in poor treatment responses and
high failure rates [18]. These poor clinical outcomes are
observed irrespective of the primary treatment type, either
a surgical approach with radical prostatectomy (RP) or
radiotherapy with external-beam radiation therapy (EBRT)
or brachytherapy. A study by Pisansky et al., assessed disease
relapse in 500 patients with clinically localized prostate
cancer treated solely with radiotherapy. The total RT dose
administered was dependent on tumor stage: T1 received
a median dose of 64Gy (range 60–70.7Gy); T2 64.8Gy
(range, 50–70.2Gy); T3-4, 66.3Gy (range, 55.8–70.4Gy).
Amongst high-risk patients, a 24% relapse-free probability
at 5 years as well as a much higher incidence of clinical and
biochemical relapse was reported when compared to their
low and intermediate risk counterparts [19]. Furthermore,
a 2005 multi-institutional review by Soloway and Roach
further delineated the need to improve existing therapeutic
interventions. High-risk patients undergoing monotherapy
with curative intent with RP, EBRT, or brachytherapy had
high rates of both clinical and biochemical progressions
(>50% at 5 years). Importantly, this paper also alluded to the
increasing importance of adjuvant therapy and multimodal
approachesin ordertoimprove controlofhigh-risk localized
disease [20].
3. CurrentRecommendations for Management
of High-Risk ProstateCancer
3.1. Radiotherapy as a Treatment Option in High-Risk Pros-
tate Cancer. Technological advances in existing treatment
modalities and the combination of local and hormonal
therapies have led to considerable progress in disease control
and survival outcomes. Radiotherapy has been and will
continue to be a key component in the treatment of prostate
cancer and much eﬀort has been dedicated to increasing its
therapeutic eﬃcacy with new techniques to deliver radiation.
The advent of three-dimensional conformal radiation ther-
apy (3D-CRT) and intensity-modulated radiation therapy
(IMRT) have allowed radiation oncologists to achieve safe
dose escalation while limiting local tissue toxicities classically
associated with EBRT, such as genitourinary and bowel
complications. Several independent studies have conﬁrmed
that dose escalation is associated with improved biochemical
outcomes in addition to a lower risk of radiation-associated
late side eﬀects [21–25]. A pivotal randomized control trial
by Kuban et al. at M.D. Anderson Cancer Center served
to validate doses as high as 75–80Gy as a permissible dose
escalation for the high-risk cohort. Among the 301 patients
enrolled in this long-term study, the subset of patients with
adverse prognostic features (PSA > 10ng/mL at diagnosis)
derived the greatest beneﬁt at a dose of 78Gy compared
to 70Gy, in terms of biochemical and clinical failure [26].
Furthermore, with increasing doses, accurate and precise
delivery of radiation using technology such as image-guided
radiation therapy (IGRT) becomes even more important
to avoid normal tissue toxicities. IGRT should also be
considered in order to compensate for changes in target
volume as the tumor shrinks.
Recently, both volumetric-modulated arc therapy
(VMAT) and helical tomotherapy techniques have been
evaluated as novel ways to deliver radiotherapy. Several
preliminary studies have evaluated the dosimetric feasibility
of treating a broad spectrum of prostate cancer with VMAT,
including localized, locally advanced and postoperative
disease [27, 28]. A retrospective review of 292 patients
treated with a VMAT method to a dose of 77.4Gy was
compared to a ﬁxed-angle, 7-ﬁeld IMRT technique using the
same planning datasets and contours. It was reported that
VMAT therapy resulted in a lower dose of delivery to critical
structures such as the penile bulb, bladder, and femoral
heads, particularly in high-dose regions with comparable
dose delivery to target volumes when compared to IMRT.
These results suggest further evaluation of VMAT in order
to reduce radiotherapy-related acute and chronic toxicities
[29]. Similar dosimetric studies evaluating the ability of
helical tomotherapy to improve dose conformity and normal
tissue sparing in comparison to IMRT have demonstrated
overall improvement in critical organ sparing as well as
achieving better homogeneity of dose delivery [30]. Of note,
the improving precision and dose escalation in the admin-
istration of radiotherapy to target volumes has lead to the
development of simultaneous integrated boost radiotherapy,
which delivers diﬀerent doses per fraction to diﬀerent target
regions of interest. Consequently, whole pelvis radiation
therapy, which has traditionally been a controversial issue,
is now a valid therapeutic consideration for node-positive or
high-risk patients because high doses can be delivered to a
focal target volume while also administering a lower dose of
RT to the rest of the pelvis which may promote locoregional
control and address micrometastatic disease [31].
3.2. Androgen Deprivation Therapy (ADT) in Combination
with Radiotherapy. Arguably, combination therapy with
radiation and long-term androgen deprivation therapy4 Advances in Urology
(ADT) has been one of the most important modiﬁcations
to modern clinical practice for prostate cancer. The rationale
of the combined approach is that the addition of ADT is
believed to slow progression of the tumor by eliminating
the hormonal stimulus that drives cancer cell proliferation
[32]. Furthermore, in vivo animal models have shown that
the combined eﬀect of ADT and radiotherapy increases
overall cell kill and diminishes growth velocity of the
surviving cancer cells [33, 34]. Several agents, such as
luteinizing hormone-releasing hormone (LHRH) analogs
and nonsteroidal antiandrogens have been used to exploit
the sensitivity of prostate cancer to hormonal suppression.
Of note, surgical (bilateral orchiectomy) and medical cas-
tration are of equal eﬃcacy and using multiple methods of
androgen blockade does not confer an additive beneﬁt for
nonmetastatic patients [35].
Several prospective studies have demonstrated that the
combination of radiotherapy and long-term androgen sup-
pression improves disease control and survival, compared
witheithertreatmentaloneformenwithadverseriskfactors.
A prospective phase III trial, EORTC 22863, enrolled 415
men randomized to either radiotherapy alone or radio-
therapy plus three years of LHRH analog (goserelin) to
assess the additive eﬀect long-term ADT in locally advanced
patients. The study reported an increase in both disease-
free and overall survival in the combination therapy group.
Furthermore, the 10-year results of this study found no
increase in cardiovascular toxicity in addition to the survival
beneﬁt [36–38]. In 2009, a prospective randomized study by
Widmark et al. involving 875 high-risk patients (stage T3,
PSA < 70ng/mL) receiving ADT monotherapy (total andro-
gen blockade for 3 months followed by continuous ﬂutamide
250mg) or ADT with radiotherapy also demonstrated a
survival beneﬁt with a minimal yet acceptable increase in
side eﬀects in the combination therapy cohort [39]. Similar
ﬁndings were reported by D’Amico et al. in 2008, who
reported an overall survival beneﬁt in high-risk patients
receiving combination therapy, despite a shorter course of
ADT treatment than the aforementioned studies [40].
The optimal duration of ADT has been a controversial
topic, and several studies have examined whether or not
the long-term side eﬀects of ADT outweigh the clinical
beneﬁts. It is understood that the incidence of side eﬀects
correlates with the duration of ADT treatment. Long-term
complications associated with ADT are both real and severe,
ranging from osteoporosis with risk of pathologic fracture,
metabolic dysfunction including development of diabetes as
wellascardiovasculardiseasewithpotentialforfatalmyocar-
dial infarction [41, 42]. In 2009, Bolla et al. reported the
results of the prospective EORTC 22961 trial randomizing
885 men with T2c-T4, N0 disease, in order to assess whether
short-term ADT (6 months) was able to achieve the same
survival beneﬁts that had previously been reported with
long-term ADT (≥2 years) while simultaneously reducing
exposure to hormonal therapy. The 5-year overall mortality
rate was 19.0% and 15.2% for short-term and long-term
ADT, respectively; demonstrating that short-term ADT in
conjunction with radiotherapy is inferior with regards to
overall survival [43].Furthermore,RTOG9202,alargephase
III trial of 1554 patients with T2c-T4 non-metastatic high-
risk disease, reported that long-term ADT with radiotherapy
is superior to short-term ADT with regards to disease-
free survival, risk of distant metastasis, local progression
and incidence of biochemical failure; however, no diﬀerence
in overall survival was observed. A criticism of this study
by Horwitz and colleagues is that it was not suﬃciently
powered to assess for overall survival. Upon subset analysis
of 337 patients with a Gleason score 8–10 a beneﬁt in
overall survival was seen in the long-term ADT cohort
[44]. A Canadian multicenter phase III trial examining
short-versus long-term neoadjuvant ADT in combination
with radiotherapy found that increasing the duration of
neoadjuvant ADT from 3 to 8 months conferred a signiﬁcant
disease-free survival beneﬁt among high-risk patients (42%
versus 71% 5-year disease-free survival rate) [45]. While
the duration of ADT has deﬁnitively demonstrated an eﬀect
on patient survival, the sequencing (adjuvant, concurrent,
neoadjuvant) of when ADT is administered in relation to
radiotherapy does not appearto aﬀectoutcomesinmenwith
high-risk prostate cancer [46–48].
In summary, the current standard of care for high-risk
and locally advanced disease is EBRT in conjunction with
long-term ADT; speciﬁcally, a 3D-CRT or IMRT radiation
therapy technique to a dose of 75–80Gy in conjunction
with long-term ADT in a neoadjuvant, concurrent, or
adjuvant setting for approximately 2-3 years. Generally,
high-risk patients are usually not considered for treatment
with brachytherapy; however, certain clinical scenarios may
warrant the use of brachytherapy boost in combination
with EBRT, with consideration of short-term ADT [49].
Additionally, a surgical approach may be considered for
selected high-risk-patients, although, it is a seemingly less
popular approach due to the invasive nature in comparison
to EBRT as well as the distinct set of complications which
surgery poses; including perioperative mortality, long-term
sexual dysfunction, and urinary incontinence. Additionally,
the high likelihood that postoperative radiotherapy will be
required potentially exposes patients to toxicities of both
surgery and radiotherapy.
3.3. Surgery as a Treatment Option for High-Risk Prostate
Cancer. Like radiotherapy, as technology (i.e., laparoscopic,
robotic) continues to improve, some of the issues with
surgical management for high-risk patients are no longer
valid. For example, with the advent of robotic surgery
some experienced urologists now consider stage T3a prostate
cancer as an operable disease. Men with clinically localized
tumors without ﬁxation that can be completely excised
may be candidates for radical prostatectomy (RP) with
pelvic lymph node dissection if they have a reasonable
life expectancy. Lau et al., reported a post-RP overall
survival of 67% at 10 years among patients with adverse
prognostic features (Gleason score ≥ 8), suggesting that
radical prostatectomy may be a viable alternative for patients
who are not candidates for radiotherapy or whom prefer
surgery [50].
Additionally, two recent studies have shown that surgical
intervention in the high-risk cohort may result in superiorAdvances in Urology 5
clinical and survival outcomes. A 2010 retrospective study by
Zelefsky et al., reported that high-risk patients undergoing
RP had a lower risk of metastatic progression and PCSM
compared to patients receiving IMRT (≥81Gy) [51]. High-
risk disease was deﬁned as clinical stage T3, Gleason score 8–
10, or PSA > 20ng/mL; within this subgroup those patients
treated with RP with bilateral lymphadenectomy had a 7.8%
decrease in 8-year metastatic progression compared to those
treated with RT (hazard ratio, 0.35). Furthermore, a 2010
retrospective analysis by Abdollah et al. examined survival
outcomes patients treated with RP, RT, or observation
between 1988 and 2006 and noted favorable survival rates
in most patients undergoing RP [52]. Amongst high-risk
patients (T2c and/or Gleason score 8–10), patients ≤ 69
years of age treated with RP derived the greatest survival
beneﬁt (PCSM 5.8–7.2%) in comparison to those treated
with RT or observed (PCSM 9.9–11.3% and 21.5–21.9%,
resp.). However, among patients older than 70 years of
age, treatment with RT was associated with a lower PCSM
(12.2–21.1%) when compared to those treated with RP or
observation (PCSM = 12.2–21.1%, 18.5–19.8%, resp.).
A signiﬁcant number of patients will still require post-
operative radiotherapy following radical prostatectomy for
certain pathologic high-risk features. Recently, three sepa-
rate studies have demonstrated that adjuvant radiotherapy
following radical prostatectomy improves disease control
(biochemical progression-free survival), and Thompson et
al. reported a marked overall survival beneﬁt for high-risk
patients following radical prostatectomy [53–56]. Further-
more, aforementioned studies by Spahn et al. and Walz et
al. have documented that men with high-risk disease do
not have uniformly poor outcomes after undergoing radical
prostatectomy.Indeed,thereisasubsetofpatientswithinthis
r i s kg r o u pt h a td e r i v eac o m p a r a t i v eb e n e ﬁ tf r o ms u r g e r y ,
and thus RP should remain a genuine consideration for
therapeutic intervention [11, 12, 57].
4. Chemotherapy and ProstateCancer
4.1. The Use of Chemotherapy in Castration-Refractory
ProstateCancer. Althoughlong-termADTplusradiotherapy
is currently the standard care for high-risk patients, many
high-risk prostate malignancies still recur. Importantly, a
proportion of these high-risk prostate tumors will become
refractory to hormonal therapies which place the patient
at risk of developing recurrent or metastatic disease [36,
58, 59]. Strategies to enhance the therapeutic beneﬁts of
treatmentand improve survival outcomeshave been studied,
with a particular emphasis on systemic treatment such
as chemotherapy. Castration-refractory metastatic prostate
cancer patients were the ﬁrst group of patients in which
the eﬃcacy of chemotherapy was assessed. The CALBG
9182 study examined a combination of mitoxantrone and
hydrocortisone versus hydrocortisone alone. While there
was no survival beneﬁt reported among the 242 men with
castration-refractory disease, a delay in disease progression
andtimetotreatmentfailurewasobserved.Additionally,this
study also conﬁrmed the palliative beneﬁts of this regimen
previously reported in a small randomized trial in Canada
[60, 61]. The CALBG 9182 study generated interest in
exploring other chemotherapeutic agents in this population.
Two prospective phase III trials for men with metastatic
castration-refractory prostate cancer helped to establish
docetaxel and prednisone as the preferred chemotherapy
regimen. SWOG 9916, a prospective trial randomizing 674
men with castration-refractory disease, compared survival
outcomesandtoxicity proﬁlesinahead-to-headcomparison
of a docetaxel plus estramustine versus mitoxantrone. The
docetaxel-containing regimen demonstrated a signiﬁcant
increase in overall survival of nearly two months; however,
there was also an increase in side eﬀects, including neu-
tropenic fever and cardiovascular events [62]. Subsequently,
it has been reported that the addition of estramustine to
docetaxel has been shown to increase side eﬀects without
enhancing eﬃciency [63]. The second pivotal study was the
TAX 327 trial which compared docetaxel and mitoxantrone;
prednisone was also administered in both regimens. Impor-
tantly, estramustine was not a component of the docetaxel-
containing regimens and docetaxel was given in a weekly or
in an every three-week schedule. Patients in the docetaxel
every three-week arm demonstrated an improved median
survival of 2.5 months with a 24% reduction in risk of death
[64]. The 10-year update of this study reported continued
survival beneﬁt in the docetaxel every three-week arm [65].
4.2. The Role for Chemotherapy in the Management of
High-Risk Localized Disease. These studies in metastatic
castration-refractory patients helped lay the groundwork for
early use of docetaxel and other agents as part of the pri-
mary treatment for high-risk and locally advanced prostate
cancer patients (Table 4). The rationale of using chemother-
apy and other systemic agents in the adjuvant setting is
that micrometastatic disease as well as androgen-resistant
clones will encounter cytotoxic treatment earlier [17]. As
radiotherapy techniques permit increasing dose escalation,
chemotherapy can play a more important synergistic role by
radiosensitizing tumor cells at the primary site while also
addressing micrometastatic disease. Speciﬁcally, docetaxel,
a radiosensitizing cytotoxic antimicrotubule agent has been
used extensively in the treatment of breast, ovarian, and
nonsmall-celllungcancer[66–68].Itexertsadirectcytotoxic
eﬀect by arresting cells in M phase, thereby preventing cell
division. Furthermore, by stabilizing the cells in M phase,
a radiosensitive phase of the cell cycle, docetaxel is able to
synergize the eﬀect of radiation [69–71].
A critical phase III multicenter study by Rosenthal et
al. highlighted the severe toxicities that may occur with
multichemotherapy multimodal regimens. A total of 397
high-risk non-metastatic patients (PSA 20–100ng/mL and
Gleason score ≥ 7 or stage > T2, Gleason score 8 and PSA <
100ng/mL) enrolled in RTOG 99-02 and were randomized
to an ADT plus radiotherapy with four cycles of adjuvant
paclitaxel, estramustine and oral etoposide (TEE) group,
or an ADT plus radiotherapy alone group. After opening
in 2000, the trial was closed after 4 years due to excess
thromboembolic events and severe toxicities, particularly in
the adjuvant chemotherapy arm. With regards to short-term
toxicities,71%(136/192)ofpatientsintheadjuvantTEEplus6 Advances in Urology
Table 4: Summary of randomized control trials involving chemotherapy for high-risk localized prostate cancer.
Study (reference) Chemo
sequencing Chemo regimen Study arms Number of
patients
High-risk criteria
Stage Gleason PSA
RTOG 9902 [14] Adjuvant paclitaxel estramustinee
toposide (TEE)
ADT + RT versus ADT
+R T+T E E 397 any T ≥7 20–100
≥ T2 8–10 <100
RTOG 0521 [15] Adjuvant Docetaxel ADT + RT versus ADT
+R T+d o c e t a x e l 612
any T ≥9 ≤150
≥ T2 8 <20
any T 7-8 ≥20–150
Kumar et al. [72] Concurrent Docetaxel RT + docetaxel 22
T3-T4
T1b-T2 ≥8
T1c-T2 5–7 ≥10
AGUSG 03-10 [73]
Concurrent Docetaxel RT + docetaxel +/−
ADT 20 ≥T3 8–10
7 >10
Sanﬁlippo et al. [74]C o n c u r r e n t P a c l i t a x e l ADT + RT versus ADT
+ RT + paclitaxel 22 TxN1 >7 >10
Hussain et al. [75] Neoadjuvant Docetaxel estramustine docetaxel, EMP +/−
RP, RT 21 ≥T2b 8–10 ≥15
Hirano et al. [76] Neoadjuvant/
concurrent Estramustine ADT + RT versus ADT
+R T+E M P 39 ≥T3 8–10 >20
SWOG S9921 [77, 78] Neoadjuvant Mitoxantrone RP + ADT versus RP +
ADT + MTX 983 pT3b-T4 ≥8
7 >15
CALGB 90203 [79] Neoadjuvant Estramustine docetaxel RP versus EMP and
docetaxel + RP recruiting T1-T3a,
NX, M0
ADT: androgen deprivation therapy; RT: radiotherapy; TEE: paclitaxel, estramustine, etoposide; EMP: estramustine phosphate; RP: radical prostatectomy;
MTX: mitoxantrone.
ADT and radiotherapy cohort reported grade 3 or greater
toxicities compared with only 37% in the radiotherapy and
ADT cohort. There was a signiﬁcant increase in hematologic
and gastrointestinal toxicity but not genitourinary toxicity.
Furthermore, in terms of long-term complications, three
cases of myelodysplasia/acute myelogenous leukemia were
noted [14]. A follow-up prospective phase III trial, RTOG
05-21, was designed to assess the eﬃcacy of a less toxic
adjuvant chemotherapy regimen when combined with ADT
and radiotherapy. This ongoing study compares high-risk
patients receiving ADT (LHRH agonist and oral antiandro-
gen)andradiation(3D-CRTorIMRT)withorwithoutadju-
vantdocetaxelchemotherapy.Enrollmentcriteriaconsistsof:
(1) Gleason score ≥ 9, PSA ≤ 150ng/mL and any T stage
disease(2)Gleasonscore8,PSA<20ng/mL,stageT2disease
or higher (3) Gleason score 7-8, PSA 20–150ng/mL, any
T stage [15]. The results of this trial will certainly help to
elucidatetheroleofchemotherapyintheadjuvantsettingfor
high-risk patients.
Kumar et al. conducted a phase I trial of concurrent
weekly docetaxel with 3D-CRT in order to discern to
maximal tolerated dose (MTD) of weekly docetaxel for
patients with unfavorable localized prostate cancer. The 22
patients who were enrolled in the concurrent docetaxel and
3D-CRT regimen met inclusion criteria of: (1) T3-T4 disease
(2) T1b-T2 disease and Gleason score ≥ 8o r( 3 )T 1 c -
T2 disease with Gleason score 5–7 and PSA ≥ 10. The
MTD of weekly docetaxel was determined to be 20mg/m2
in conjunction with 3D-CRT, in general, this regimen was
considered to be well tolerated without any excessive or
objectionable toxicity. Other relevant ﬁndings from the
study include the side eﬀect of grade 3 diarrhea which was
the dose-limiting toxicity; however, no hematologic adverse
side eﬀects were noted [72]. Another small phase I study
involving concurrent docetaxel and radiotherapy supported
Kumar’sﬁndingsofpermissibletoxicitywithradiosensitizing
regimens. The AGUSG 03-10 phase I/II prospective trial
was a continuation upon Kumar et al.’s earlier work with
docetaxel and 3D-CRT. In this study, concurrent IMRT
was given with the previously determined MTD of weekly
docetaxel at 20mg/m2. Twenty high-risk patients with at
least stage T3 disease, a Gleason score of 8–10 and PSA >
10ng/mL were enrolled on this concurrent chemoradiation
protocol. In general, the concurrent IMRT with weekly
docetaxelregimenwaswelltoleratedwithacceptabletoxicity.
Furthermore, 85% of the patients were free of biochemical
disease recurrence at a mean followup of 11.7 months. Of
note, there were no grade 3 or 4 toxicities reported and the
most common toxicities were grade 2 fatigue (40%), grade 2
diarrhea (40%), and grade 2 urinary frequency (35%) [73].
The two aforementioned studies highlighted the emerging
role that concurrent taxane-based chemotherapy may play in
the management of high-risk prostate cancer.
Sanﬁlippo et al. conducted a prospective phase I/II study
of biweekly paclitaxel and concurrent radiotherapy in order
to determine the maximum tolerated dose of paclitaxel in
androgen-ablated locally advanced prostate cancer. Pacli-
taxel, a taxane molecule, has a similar mechanism of actionAdvances in Urology 7
to docetaxel which leads to the accumulation of cells in
G2/M phase having both cytotoxic as well as radiosensitizing
eﬀects [80, 81]. This study involved 22 patients who had
T2–T4 tumors with Gleason scores > 7 and/or PSA levels
> 10ng/mL and/or pathologic staging of TxN1. Patients
underwent 3D-CRT with doses ranging from 63–73.8Gy.
It was concluded that concurrent biweekly paclitaxel with
3D-CRT is feasible with an MTD for combined paclitaxel
and 3D-CRT of 73.8Gy. Four patients developed grade 3
diarrhea, three at a dose of 66.6Gy and one at the MTD of
73.8Gy. With regards to patient outcomes, 21 of 22 patients
(95%) were still alive and 6 of 22 (27%) patients experienced
biochemically recurrent disease at a median followup of
28 months [74]. Importantly, in comparison to the afore-
mentioned studies involving concurrent radiotherapy with
paclitaxel, patients in this trial also received ADT in addition
to concurrent chemoradiotherapy and the toxicities were not
prohibitive.
Examining the eﬃcacy of chemotherapy in the neoad-
juvant setting in combination with ADT and radiotherapy
is becoming an area of increasing interest. Hussain et al.
evaluated the safety of neoadjuvant docetaxel and estramus-
tine chemotherapy alone in 21 patients with high-risk cancer
deﬁned as clinical stage T2b or greater, PSA > 15ng/mL
and/or a Gleason score of 8–10. Induction chemotherapy
with docetaxel and estramustine was reported to be a well-
tolerated and a feasible regimen for the high-risk cohort.
Patients did experience grade 3 and 4 toxicities in the form
of neutropenia in nine patients and deep vein thrombosis
in two patients. Furthermore, the eﬃcacy of this regimen
in comparison to ADT remains unclear and its use in
conjunction with other modalities was not evaluated [75].
However, a prospective randomized study in Japan assessed
thesafetyandeﬃcacyofneoadjuvantADTplusestramustine
phosphate (EMP) combined with 3D-CRT for patients
with both intermediate and high-risk prostate cancer. A
total of 39 patients were randomized into a neoadjuvant
ADT alone group or neoadjuvant ADT with EMP group,
both groups received 3D-CRT to a total dose of 70Gy.
The 4-year biochemical relapse-free survival was 61% in
the group receiving combined chemotherapy and androgen
ablation compared to the 49% in the group receiving
only neoadjuvant ADT. Additionally, there were no severe
toxicities reported leading the authors to conclude that the
combination of ADT with EMP in the neoadjuvant setting
appears to be better than neoadjuvant ADT alone. However,
both regimens were unable to prevent biochemical failure
and thus suggested additional adjuvant therapy, particularly,
in the high-risk cohort with pretreatment PSA > 20ng/mL
[76].
Recently, the role of chemotherapy in conjunction with
radical prostatectomy has also been examined. Similarly to
RTOG 99-02, which has halted due to prohibitive toxicities,
SWOG 9921, a randomized phase III trial, prematurely
closed the chemotherapy plus ADT arm due to the devel-
opment of acute myelogenous leukemias. In this study,
983 patients with high-risk features were randomized to
receive adjuvant ADT with or without mitoxantrone in
the postradical prostatectomy setting. This study underlined
the importance of prospective trials to assess potential
safety issues for patients. In this particular case, the risk
of secondary malignancies associated with a mitoxantrone-
containing adjuvant chemotherapy regimen was an unex-
pected problem [77]. Importantly, in 2011 Dorﬀ et al.
reported preliminary data from the SWOG S9921 study
because of the potential implications for future prospective
trial design. Among the 481 high-risk patients (Gleason ≥
8, preoperative PSA > 15ng/mL or both) receiving ADT-
alone after RP, the estimated 5-year biochemical failure-free
survival is 92.5% and the 5-year overall survival is 95.9%. In
light of the favorable outcomes achieved with adjuvant ADT
post-RP, this study highlights the diﬃculty in demonstrating
that the addition of chemotherapy can improve upon
currently available therapies given the extremely low rate
of disease recurrence and PCSM [78]. Of note, the cancer
and leukemia group B has initiated an ongoing phase III
trial(CALGB90203)inhigh-riskpatientsrandomizingthem
to be treated with neoadjuvant estramustine and docetaxel
followed by surgery or surgery alone [79].
5. New Approaches on the Horizon
The need to improve high-risk disease management has
prompted the development of novel agents, several of which
may be genuine contenders to impact disease outcomes in
thefuture.Initialstudiesincastration-refractorydiseasehave
been useful in order to characterize the eﬃcacy and safety of
these potential therapeutic agents.
Sipuleucel-T (APC8015), a cancer vaccine, is an active
cellular immunotherapy that stimulates a prostate cancer-
speciﬁc T-cell immune response against prostatic acid phos-
phatase (PAP), an antigen expressed by approximately 95%
of prostate cancer cells [82–84]. Speciﬁcally, autologous
antigen-presenting cells (APCs) collected via leukapheresis
undergo ex vivo stimulation with PA2024 (recombinant
f u s i o np r o t e i no fP A Pa n dG M - C S F )a n da r es u b s e q u e n t l y
infused into the patient to exert an immunogenic eﬀect.
Presumably, the interaction of T cells with the PA2024-
activated APCs primes the T cells for their highly speciﬁc
tumoricidal activity [85, 86]. A 2010 multicenter double-
blind, placebo-controlled study by Kantoﬀ et al. evaluated
a total of 512 patients with metastatic castration resistant
disease in order to compare the eﬃcacy of sipuleucel-T to
placebo. Sipuleucel-T was shown to prolong overall survival
with a 22% relative reduction in risk of death (hazard
ratio, 0.78) which prolonged median survival by 4.1 months,
however, no change in the time to disease progression was
noted. There were no excessive toxicities observed, however,
an increase in chills, fever, and headache was associated with
infusion of sipuleucel-T [87]. Sipuleucel-T was approved
by the FDA in April 2010 for the treatment of asymp-
tomatic or minimally symptomatic metastatic castration-
refractoryprostatecancer.Theearlyﬁndingswithsipuleucel-
T appear to be promising but its eﬃcacy in conjunction with
chemotherapy and potential use in earlier settings such as
high-risk prostate cancer is yet to be determined.
While prostate cancer patients often initially derive
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develop castration-refractory prostate cancer characterized
by progression of disease despite castrate levels of circulating
testosterone. The persistence of ligand-mediated androgen
receptorsignalingimplicatesextragonadal(prostate,adrenal,
intratumoral) androgen production as a potential mech-
anism of resistance to ADT rather than an androgen-
independent mechanism. Abiraterone acetate suppresses
extragonadal androgen biosynthesis via inhibition of CYP17
(cytochrome P-450c17), an enzyme that has been shown to
be over expressed in castration-refractory disease. In a recent
2011 phase III multicenter trial, de Bono and colleagues
evaluated the eﬃcacy of abiraterone in castration-refractory
patients with progression after docetaxel treatment. Patients
were randomized to receive prednisone with either abi-
raterone or placebo and there was a median follow-up time
of 12.8 months among the 1195 enrolled patients. A clear
survival beneﬁt was reported in the abiraterone-prednisone
group, with a 35.4% reduction in the risk of death compared
to the placebo cohort (hazard ratio, 0.65) which translated
into an increase in overall survival of 3.9 months (14.8
versus 13.9 months). Secondary end points including PSA
progression, progression-free survival and PSA response rate
also favored the patients whom received abiraterone. Of
note, while both treatment cohorts received prednisone as
part of the treatment regimen, steroid-related toxicities and
side eﬀects were more frequent among patients receiving
the androgen biosynthesis inhibitor. However, the general
consensus regarding this study is that abiraterone acetate
plus prednisone is eﬀective in prolonging overall survival
with minimal increase in additional toxicities for patients
with metastatic castration-refractory prostate cancer with
progression after chemotherapy [88, 89].
A new therapy, MDV3100, targets androgen receptor-
mediated treatment resistance with a distinct mechanism of
action to that of abiraterone. While the concept of androgen-
receptor antagonism is not a novel concept, MDV3100
is notable for its extremely high receptor-binding aﬃnity,
ability to induce tumor cell apoptosis and pure androgen
receptor antagonism [90]. These characteristics ensure more
eﬀectiveandrogensignalingblockadeincomparisontoother
agents such as bicalutamide that have a relatively lower
receptor binding aﬃnity and may exhibit partial agonism
at the androgen receptor; a potential cause of refractory
disease. Although, this agent is not as far along as sipuleucel-
T and abiraterone in terms of clinical testing, a phase 1-
2 study by Scher et al. has generated cautious optimism
regarding MDV3100. This multicenter dose-escalation trial
enrolled 140 patients with progression metastatic castration-
refractory disease in order to assess the safety and toler-
ability of MDV3100 as well as to establish the maximum
tolerateddose.Themaximumtolerateddosewasdetermined
to be 240mg/day and the most predominant grade 3-4
treatment-related toxicity was dose-dependent fatigue. Of
note, antitumor eﬀects were appreciated at all doses. This
study has helped to corroborate that persistent androgen-
receptor signaling is veritable target for castration-refractory
disease and further preclinical and clinical studies are need
to decided whether MDV3100 can truly impact outcomes
among prostate cancer patients [91].
6. Conclusion
While considerable progress has been made in the treatment
of high-risk prostate cancer, there is a clear need to continue
prospective randomized clinical trials in order to optimize
treatments. Combination therapies involving radiotherapy,
androgen deprivation therapy, surgery and chemotherapy
have yielded varied success. Importantly, the combination of
long-term ADT and radiotherapy and has been particularly
successful and chemotherapy may have the potential further
improve outcomes. As we continue to appreciate the additive
andsynergisticeﬀectsofmultimodalitytherapy,wemustalso
acknowledge the potential for additive toxicities.
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